Novo Nordisk (NYSE: NVO) has spent years building its reputation around treatments for diabetes and obesity, so investors have been watching its next generation drug...
Novo Nordisk
Hims & Hers Health (NYSE: HIMS) shares dropped sharply by more than 25% at market open today. This plunge came after the telehealth company quickly...
Novo Nordisk A/S (NYSE: NVO) surprised investors this week by warning that its sales may decline this year, marking the first projected drop since Ozempic...
Novo Nordisk A/S (NYSE: NVO, CPH: NOVO-B) opened trading over 9% higher after U.S. regulators cleared an oral version of its weight-loss drug Wegovy. The...
Novo Nordisk A/S (NASDAQ: NVO) recently encountered a notable setback that sent ripples through its stock price and raised questions about the company’s strategic direction....
Novo Nordisk (NYSE: NOVO) has announced a significant 30% reduction in the cash price of its obesity drug Wegovy, a change aimed at broadening patient...
Novo Nordisk (Nasdaq: NVO) made headlines today with a move that could mark a turning point for self-paying Americans managing diabetes and obesity. The Danish...
